Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613190 | 0.91 | CTSD (0.32) | JAK3FEN1 | |
| SCHEMBL25613062 | 0.84 | JAK3 (0.39) | JAK1POLBJAK3FEN1 | |
| SCHEMBL25613086 | 0.82 | JAK3 (0.46) | JAK1JAK3FEN1 | |
| SCHEMBL25613075 | 0.82 | JAK3 (0.43) | JAK1JAK3FEN1 | |
| SCHEMBL25613105 | 0.81 | JAK2 (0.35) | JAK1FEN1 | |
| SCHEMBL25613082 | 0.81 | JAK3 (0.48) | JAK1JAK3FEN1 | |
| SCHEMBL25613083 | 0.80 | LRRK2 (0.40) | JAK1JAK3 | |
| SCHEMBL25613078 | 0.80 | PIK3CD (0.33) | JAK3FEN1 | |
| SCHEMBL25613085 | 0.80 | ROCK1 (0.41) | JAK3FEN1 | |
| SCHEMBL25613079 | 0.79 | FEN1 (0.34) | JAK3FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | GRM4 4756/4885JAK1 3603/4885PDE4B 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.